#USA #New York #Class Action #Pomerantz LLP #Picard Medical

Investor Alert: Class Action Against Picard Medical, Inc.

In a significant development for investors, Pomerantz LLP has announced the filing of a class action lawsuit against Picard Medical, Inc. (NYSE: PMI). This lawsuit is aimed at addressing concerns over alleged securities fraud and other unlawful business practices related to the company's stock performance. Investors who have experienced losses during their investment in Picard Medical should pay close attention to the upcoming deadlines and opportunities for involvement in this case.

Details of the Class Action

Important Contact Information

Those impacted by the situation or who wish to participate in the class action are encouraged to reach out to Danielle Peyton from Pomerantz LLP via email at [email protected] or by phone at 646-581-9980. The toll-free number for inquiries is 888-4-POMLAW, extension 7980. When contacting via email, investors should include their mailing address, phone number, and details on the number of shares purchased.

Legal Context

The crux of the class action centers around alleged securities fraud. Specifically, the lawsuit investigates whether certain officers and/or directors of Picard Medical engaged in practices that were misleading to investors. This class action presents a chance for affected shareholders to hold the company accountable for any potential misconduct.

Historical Context of Picard Medical's Stock

In a notable series of events, between the weeks leading up to October 23, 2025, the stock price of Picard soared dramatically from its initial public offering (IPO) price of $4.00 per share, reaching an unprecedented high of $13.68 per share. This surge occurred without any fundamental business updates that would normally justify such a substantial increase.

Investigations have since uncovered that this spike was not based on legitimate market activity but was instead influenced by an illicit promotion scheme on social media. Impersonators posing as credible financial advisors made unwarranted claims that contributed to a buying frenzy among retail investors, leading to artificially inflated stock valuations.

The Role of Pomerantz LLP

Pomerantz LLP is recognized as a leading firm when it comes to corporate, securities, and antitrust class litigation. Established by the late Abraham L. Pomerantz, who was a pioneer in the field of securities class actions, the firm has a long-standing tradition of fighting for investors' rights.

Over its more than 85 years of history, Pomerantz has successfully secured numerous multimillion-dollar awards for victims of securities fraud and has made an indelible impact in the realm of corporate accountability. Interested parties can learn more about the firm's history and its current cases by visiting www.pomerantzlaw.com.

How to Get Involved

Investors with losses related to Picard Medical's shares have until April 3, 2026, to request the Court to appoint them as Lead Plaintiff in the class. For those who purchased or otherwise acquired Picard securities during the identified Class Period, joining this class action may provide an avenue for potential recovery of losses.

If you believe you have a claim or wish to monitor the developments of this case closely, do not hesitate to seek legal counsel or contact Pomerantz LLP for guidance.

Conclusion

This class action serves as a critical reminder to investors about the importance of transparency and accountability in the financial markets. As operations like Picard Medical come under scrutiny, investor vigilance remains paramount. Keep informed, stay involved, and understand your rights as a shareholder to potentially recover from any losses incurred due to misleading practices.

Whether you’re a seasoned investor or new to the market, it’s essential to stay updated on such legal proceedings that might impact your investment strategies.